Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Trial Profile

Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2018 The study has been completed in Italy.
    • 02 Jun 2018 The study has been completed in Germany (End date: 2018-02-10).
    • 30 May 2018 The study has been completed in Netherlands.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top